BioCryst Pharmaceuticals Inc. (BCRX) stands at the threshold of a regulatory decision that could reshape its role in treating hereditary angioedema in children, as the U.S. FDA is scheduled to deliver its decision on December 12, 2025, on the company's New Drug Application for ORLADEYO (berotralstat) Oral Granules, a once-daily formulation designed specifically for pediatric patients aged 2 to 11 years.
Oral Granules Aim to Ease Pediatric Treatment Burden
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com